持田製薬の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2024/12/19 | 3,450 | 3,525 | 3,420 | 3,475 | +25 | +0.7% | 22,000 |
2024/12/18 | 3,470 | 3,485 | 3,445 | 3,450 | -20 | -0.6% | 12,100 |
2024/12/17 | 3,470 | 3,510 | 3,455 | 3,470 | ±0 | ±0% | 17,300 |
2024/12/16 | 3,480 | 3,490 | 3,445 | 3,470 | +5 | +0.1% | 14,900 |
2024/12/13 | 3,510 | 3,590 | 3,450 | 3,465 | -110 | -3.1% | 31,900 |
2024/12/12 | 3,565 | 3,620 | 3,565 | 3,575 | +45 | +1.3% | 30,600 |
2024/12/11 | 3,550 | 3,565 | 3,530 | 3,530 | ±0 | ±0% | 16,600 |
2024/12/10 | 3,600 | 3,610 | 3,530 | 3,530 | -75 | -2.1% | 15,300 |
2024/12/09 | 3,610 | 3,625 | 3,585 | 3,605 | +10 | +0.3% | 30,000 |
2024/12/06 | 3,545 | 3,595 | 3,510 | 3,595 | +90 | +2.6% | 31,300 |
2024/12/05 | 3,475 | 3,550 | 3,475 | 3,505 | +10 | +0.3% | 30,000 |
2024/12/04 | 3,495 | 3,525 | 3,475 | 3,495 | -40 | -1.1% | 16,000 |
2024/12/03 | 3,400 | 3,535 | 3,400 | 3,535 | +150 | +4.4% | 47,600 |
2024/12/02 | 3,325 | 3,420 | 3,325 | 3,385 | +55 | +1.7% | 21,100 |
2024/11/29 | 3,365 | 3,370 | 3,325 | 3,330 | -40 | -1.2% | 16,700 |
2024/11/28 | 3,310 | 3,370 | 3,300 | 3,370 | +70 | +2.1% | 14,800 |
2024/11/27 | 3,310 | 3,340 | 3,270 | 3,300 | -20 | -0.6% | 10,900 |
2024/11/26 | 3,345 | 3,345 | 3,285 | 3,320 | +10 | +0.3% | 16,300 |
2024/11/25 | 3,335 | 3,340 | 3,305 | 3,310 | -5 | -0.2% | 19,200 |
2024/11/22 | 3,335 | 3,335 | 3,295 | 3,315 | -5 | -0.2% | 6,800 |
2024/11/21 | 3,285 | 3,345 | 3,285 | 3,320 | +60 | +1.8% | 10,900 |
2024/11/20 | 3,290 | 3,320 | 3,260 | 3,260 | -65 | -2% | 9,100 |
2024/11/19 | 3,335 | 3,375 | 3,320 | 3,325 | -20 | -0.6% | 11,000 |
2024/11/18 | 3,300 | 3,355 | 3,300 | 3,345 | +15 | +0.5% | 14,200 |
2024/11/15 | 3,390 | 3,390 | 3,330 | 3,330 | -25 | -0.7% | 11,500 |
2024/11/14 | 3,390 | 3,390 | 3,335 | 3,355 | +5 | +0.1% | 10,000 |
2024/11/13 | 3,305 | 3,380 | 3,295 | 3,350 | +50 | +1.5% | 27,000 |
2024/11/12 | 3,350 | 3,350 | 3,300 | 3,300 | -30 | -0.9% | 16,600 |
2024/11/11 | 3,300 | 3,345 | 3,230 | 3,330 | -10 | -0.3% | 9,400 |
2024/11/08 | 3,410 | 3,415 | 3,335 | 3,340 | -30 | -0.9% | 26,800 |
2024/11/07 | 3,305 | 3,375 | 3,265 | 3,370 | +105 | +3.2% | 35,500 |
2024/11/06 | 3,280 | 3,300 | 3,235 | 3,265 | -15 | -0.5% | 29,700 |
2024/11/05 | 3,255 | 3,280 | 3,175 | 3,280 | -30 | -0.9% | 49,900 |
2024/11/01 | 3,440 | 3,505 | 3,305 | 3,310 | -200 | -5.7% | 44,900 |
2024/10/31 | 3,495 | 3,550 | 3,470 | 3,510 | +40 | +1.2% | 46,400 |
2024/10/30 | 3,470 | 3,490 | 3,415 | 3,470 | +65 | +1.9% | 181,300 |
2024/10/29 | 3,410 | 3,440 | 3,400 | 3,405 | -5 | -0.1% | 12,800 |
2024/10/28 | 3,400 | 3,435 | 3,370 | 3,410 | +45 | +1.3% | 24,100 |
2024/10/25 | 3,415 | 3,420 | 3,355 | 3,365 | -75 | -2.2% | 20,400 |
2024/10/24 | 3,445 | 3,470 | 3,425 | 3,440 | ±0 | ±0% | 19,300 |
2024/10/23 | 3,480 | 3,510 | 3,435 | 3,440 | -25 | -0.7% | 15,600 |
2024/10/22 | 3,535 | 3,535 | 3,435 | 3,465 | -45 | -1.3% | 20,900 |
2024/10/21 | 3,550 | 3,550 | 3,490 | 3,510 | -25 | -0.7% | 21,700 |
2024/10/18 | 3,470 | 3,545 | 3,470 | 3,535 | +75 | +2.2% | 26,000 |
2024/10/17 | 3,445 | 3,480 | 3,440 | 3,460 | +10 | +0.3% | 12,400 |
2024/10/16 | 3,425 | 3,495 | 3,425 | 3,450 | -10 | -0.3% | 13,500 |
2024/10/15 | 3,470 | 3,485 | 3,435 | 3,460 | +25 | +0.7% | 19,400 |
2024/10/11 | 3,440 | 3,470 | 3,430 | 3,435 | -30 | -0.9% | 18,700 |
2024/10/10 | 3,485 | 3,485 | 3,405 | 3,465 | +5 | +0.1% | 12,900 |
2024/10/09 | 3,480 | 3,500 | 3,455 | 3,460 | ±0 | ±0% | 17,900 |
101~
150
件表示中 / 3705件
類似銘柄と比較する
現在ご覧いただいている「持田薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
持田薬 | 297,600円 | +5.1% | -7.0% | 2.69% | 19.54倍 | 0.81倍 |
|
医薬中堅。高脂血症薬、降圧薬など循環器系得意。婦人科系にも強み。消化器系育成。化粧品も |
ジーエヌアイ | 297,100円 | +21.7% | +999.9% | 0.00% | 12.45倍 | 4.12倍 |
|
中国の特発性肺線維症で高シェア、肺線維症後続薬進出。米国で人工骨も。米中に研究開発機能 |
ゼリア新薬 | 213,700円 | +3.1% | -6.5% | 2.25% | 9.92倍 | 1.05倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
杏林製薬 | 146,000円 | -2.4% | -52.3% | 3.90% | 17.47倍 | 0.62倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
栄研化 | 200,000円 | +4.1% | -3.1% | 2.90% | 17.54倍 | 1.53倍 |
|
臨床検査薬大手。便潜血検査試薬(FIT)はシェア7割。尿検査(ウロ)、遺伝子検査も育成 |
市場注目の銘柄
チャート関連のコラム